OTTAWA — The use of oral rather than intravenous (IV) steroids to respond to relapses in patients with relapsing-remitting multiple sclerosis (RRMS) is growing, a study suggested. The data, which were presented in a moderated poster session at the annual meeting of the Canadian Neurological Sciences Federation (CNSF) Congress 2025 , indicate a decreasing reliance on steroids over time to manage relapses.

Researchers retrospectively examined data from 2010 to 2022 from the MS database MuSicaL. Investigators identified 2413 eligible patients for their analysis, and 1086 had at least one attack or relapse. Of these 1086 patients, half (543) had used high-dose steroids for 818 attacks. Information on the route of high-dose steroids was known in 348 attacks. IV steroids were administered for

See Full Page